Andrew Crook leads the offering at Clifford Chance, with draws on the firm’s wider Greater China team to assist with a broad array of inbound and outbound China-related M&A. Emma Davies leads the firm’s healthcare and life sciences team, and is well-known for handling M&A and corporate restructuring mandates, and Virginia Lee is an expert in matters involving minority investments and share buy-back programmes. With ample expertise in the infrastructure and energy transition spaces, Alex Bidlake is a key figure within the team for joint ventures and corporate finance matters, while public M&A specialist Tommy Tam regularly assists investment banking clients and listed companies.
Legal 500 Editorial commentary
Phone
+852 2825 8828
Email
Profile

Profile

Position

Emma Davies heads Clifford Chance's Asia Pacific Healthcare & Life Sciences Sector Group. She has 25 years of experience advising clients on M&A, private equity and corporate restructuring matters. In addition, she led the China Corporate/M&A group in Shanghai from 2002–2012 and founded the firm’s China antitrust practice. Emma is fluent in Mandarin Chinese.

Career

Cambridge University (BA, Economics) 1988
Admitted as a solicitor in England & Wales 1995
Joined Clifford Chance 1997
Admitted as a solicitor in Hong Kong 1997
Seconded to Zheng, Liu, Yuan & Zhou law office, Beijing 1997-1998
Partner since 2004

Content supplied by Clifford Chance

Testimonials

Collated independently by Legal 500 research team.

  • ‘The Clifford Chance team can provide high-quality and guaranteed services. Its professional skills and service capabilities are good.’

Key clients

  • Essity AB
  • Volkswagen Group
  • China Baowu Group
  • Zhejiang Leapmotor Technology Co., Ltd.
  • NWS Holdings
  • AIA Group
  • Red Star Macalline Holding Group Company Limited
  • Pfizer
  • China Merchants Port Holdings Company Limited
  • State Grid International Development